What is the total value of India's pharmaceutical export to Norway?

India exported pharmaceuticals worth $59.9K to Norway across 35 verified shipments.

Who are the top Indian pharmaceutical exporters to Norway?

1. YASHRAJ BIOTECHNOLOGY LIMITED — $28.5K. 2. MAHARISHI AYURVEDA PRODUCTS PRIVATE LIMITED — $12.7K. 3. ORGANIC INDIA PRIVATE LIMITED — $5.7K. Total: 9 suppliers.

Which companies in Norway import pharmaceuticals from India?

1. SERO BILLINGSTAD LAGER — $28.5K. 2. XXURNXX AS — $12.7K. 3. GOODLIFE NORGE AS — $5.7K. 11 buyers total.

What pharmaceutical products does India export most to Norway?

1. Psa Act Complex Batch Fpact0039 Laboratory Raw Material to Be Used to Make Invi… ($28.5K, 47.6%); 2. Herbal Preperations ($12.7K, 21.2%); 3. Medicaments of Ayurvedic System ($4.5K, 7.4%); 4. Axiostat 25x25mm (box of 15 Units)v25 ($3.2K, 5.3%); 5. Axiostat 25x25 Mm (box of 15 Units)v25 ($2.1K, 3.6%)

Which ports handle pharmaceutical shipments from India to Norway?

Export: Bombay Air Cargo, INDORE SEZ, NHAVA SHEVA SEA (INNSA1), DELHI AIR, AHEMDABAD AIR. Import: BERGEN, OSLO, Oslo.

Why does Norway import pharmaceuticals from India?

India's cost-competitive generic drug manufacturing, WHO-GMP certified facilities, and broad product portfolio. This $59.9K corridor reflects quality compliance and pricing advantages.

What certifications do Indian pharmaceutical exporters need to supply Norway?

WHO-GMP certification, EU GMP approval (for EU markets), product dossier registration (CTD format), and ICH guideline compliance.

What is the average shipment value for India to Norway pharmaceutical trade?

$1.7K per consignment across 35 shipments.

How many Indian pharmaceutical companies export to Norway?

9 Indian companies. Largest: YASHRAJ BIOTECHNOLOGY LIMITED with $28.5K.

How can I find verified Indian pharmaceutical suppliers for Norway?

TransData Nexus covers 9 active exporters with shipment history and trade values at transdatanexus.com.

India to Norway Pharmaceutical Export (2026) — $59.9K, 9 Suppliers | TransData Nexus

India to Norway Pharmaceutical Export (2026) — $59.9K, 9 Suppliers | TransData Nexus | TransData Nexus

Top Pharmaceutical Formulations — India to Norway

#	Formulation	Value	Share
1	Psa Act Complex Batch Fpact0039 Laboratory Raw Material to Be Used to Make Invi…	$28.5K	47.6%
2	Herbal Preperations	$12.7K	21.2%
3	Medicaments of Ayurvedic System	$4.5K	7.4%
4	Axiostat 25x25mm (box of 15 Units)v25	$3.2K	5.3%
5	Axiostat 25x25 Mm (box of 15 Units)v25	$2.1K	3.6%
6	EU Tulsi Sleep New 25 Ib (organic) B/n:ebp0522 E/d:04.11.2026	$1.2K	2.0%
7	EU Tulsi Peppermint 25 Ib Organic Medicaments of Ayurvedic System B N Bb5d160591	$1.1K	1.8%
8	Pure Shilajit 30g B.no- 340624 Mfg 06/2024, Exp 05/2027	$1.0K	1.7%
9	EU Tulsi Lax 25 Ib (organic) B/n:ebp0513 E/d:04.11.2026	$702	1.2%
10	Ayurvedic Products-santhwanam Oil 5 Ltrus Bottle	$594	1.0%
11	EU Tulsi Tummy New 25 Ib (organic) B/n:ebp0525 E/d:04.11.2026	$468	0.8%
12	EU Tulsi Tummy New 25 Ib Organic Medicaments of Ayurvedic System B N Bb5d160592…	$458	0.8%
13	EU Tulsi Brahmi 25 Ib (organic) B/n:ebp0501 E/d:04.05.2027	$432	0.7%
14	EU Tulsi Raspberry Peach New 25 Ib Organic Medicaments of Ayurvedic System B N…	$423	0.7%
15	EU Tulsi Honey Chamomile 25 Ib Organic Medicaments of Ayurvedic System B N Bb5d…	$423	0.7%

India exports 20+ pharmaceutical formulations to Norway with a combined trade value of $59.9K. Key products include Herbal ($13K), Ayurvedic ($4K). These are finished dosage forms — tablets, capsules, injectables, and combination drugs — shipped from Indian manufacturing facilities with FDA, WHO-GMP, and EU GMP certifications. Data from 35 verified Indian Customs (DGFT) shipment records.

Top Pharmaceutical Products — India to Norway Trade Routes

1Herbal$13K

2Ayurvedic$4K

These are the top pharmaceutical products exported from India to Norway, each with a dedicated trade route analysis page. Click any product to see detailed export data including Indian suppliers, Norway buyers, regulatory requirements, and logistics for that specific product corridor. Products include Herbal ($13K), Ayurvedic ($4K) — all finished pharmaceutical formulations verified from Indian Customs (DGFT) records.

Top Indian Exporters to Norway

1Yashraj Biotechnology Limited

$29K

2Maharishi Ayurveda Products Private Limited

$13K

3Organic India Private Limited

$6K

4Axio Biosolutions Private Limited

$5K

5Popat Raja And Sons

$5K

Port Analysis — India to Norway Pharmaceutical Shipments

Indian Export Ports

Bombay Air Cargo2.9%

INDORE SEZ5.7%

NHAVA SHEVA SEA (INNSA1)8.6%

DELHI AIR20.0%

AHEMDABAD AIR2.9%

Norway Import Ports

BERGEN2.9%

OSLO57.1%

Oslo28.6%

Trade Statistics

Total Value$60K

Shipments35

Indian Exporters9

Norway Buyers11

Avg Shipment$2K

Products28

Other Destinations

United States$8.8B United Kingdom$1.2B Canada$1.1B France

Last updated: March 28, 2026

India–Norway Pharmaceutical Trade Corridor Analysis

Historical evolution, India's market position, and recent developments

1Trade Corridor Evolution

The India-Norway pharmaceutical trade corridor has experienced modest growth over the past decade. In 2024, India exported pharmaceutical products worth approximately $141,000 to Norway, with a significant increase to $37.88 million in 2025. This surge indicates a strengthening trade relationship, likely driven by Norway's increasing demand for diverse pharmaceutical products and India's expanding export capabilities.

Key milestones include the establishment of direct shipping routes and the recognition of India's Good Manufacturing Practices (GMP) by Norwegian authorities. These developments have facilitated smoother logistics and enhanced product acceptance in the Norwegian market. The growth trajectory suggests a promising future for bilateral pharmaceutical trade, with potential for further expansion as both nations deepen their economic ties.

2India's Market Position

India's share in Norway's pharmaceutical imports remains relatively small but is on an upward trend. In 2025, Norway's total pharmaceutical imports were valued at $785.55 million, with imports from India accounting for approximately $37.88 million. This positions India as a growing supplier, though it still holds a modest share compared to other origins.

Strategically, India's competitive advantages—such as cost-effective manufacturing, a broad portfolio of generic and branded medicines, and adherence to international quality standards—enhance its appeal to Norwegian buyers. As Norway seeks to diversify its pharmaceutical sources and manage healthcare costs, India's role is expected to become increasingly significant.

Norway Regulatory Landscape for Indian Pharmaceutical Exports

Registration process, GMP requirements, import documentation

1Registration Process

Indian pharmaceutical companies seeking to export to Norway must navigate a structured registration process. The Norwegian Medicines Agency (NOMA) requires that all medicinal products, including those from non-EEA countries like India, obtain a marketing authorization (MA) before entering the Norwegian market.

The application for MA must include comprehensive documentation, such as a detailed product dossier, evidence of Good Manufacturing Practice (GMP) compliance, and a certificate of pharmaceutical product (CPP). The dossier should adhere to the Common Technical Document (CTD) format, ensuring consistency and clarity. The evaluation process typically takes several months, depending on the complexity of the product and the completeness of the submission.

Additionally, bioequivalence studies may be required for generic products to demonstrate therapeutic equivalence to the reference product. This requirement ensures that imported generics meet the same safety and efficacy standards as their branded counterparts.

2GMP & Facility Requirements

Norwegian regulations mandate that pharmaceutical products imported from non-EEA countries, including India, be manufactured in facilities adhering to GMP standards equivalent to those in the EEA. This ensures that imported medicines meet the quality and safety standards expected in Norway.

The inspection process involves a thorough evaluation of the manufacturing facility's compliance with GMP guidelines. Norwegian authorities may conduct inspections or accept reports from recognized international bodies to verify compliance. Mutual recognition agreements between Norway and India can streamline this process, facilitating smoother trade relations.

3Import Documentation

Importing pharmaceutical products into Norway requires specific documentation to ensure compliance with regulatory standards. Key documents include the marketing authorization (MA), a certificate of pharmaceutical product (CPP), and a certificate of analysis (CoA) for each batch. These documents verify the product's quality, safety, and efficacy.

Customs procedures for pharmaceutical imports into Norway involve detailed inspections and verifications to prevent the entry of substandard or counterfeit medicines. The Norwegian Customs and NOMA collaborate to enforce these regulations, ensuring that all imported pharmaceutical products meet the required standards.

TransData Nexus Research · Norway regulatory databasesMar 2026

Product Categories & Therapeutic Trends — India to Norway

Dominant categories, emerging opportunities, and demand drivers

1Dominant Categories

India's pharmaceutical exports to Norway are predominantly in the form of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. These products align with Norway's healthcare needs, which emphasize the availability of generic medicines to manage healthcare costs effectively.

The dominance of Ayurvedic and herbal preparations in exports reflects a growing interest in alternative medicine in Norway. Products like Ayurvedic medicaments and herbal preparations cater to the Norwegian market's demand for natural and holistic health solutions.

2Emerging Opportunities

The global pharmaceutical industry is witnessing patent expirations, leading to increased demand for biosimilars and generic drugs. India, with its robust generic manufacturing capabilities, is well-positioned to meet this demand in Norway. Additionally, emerging therapeutic areas such as oncology and immunology present new opportunities for Indian exporters to introduce innovative treatments to the Norwegian market.

The Norwegian government's focus on sustainable healthcare solutions also opens avenues for Indian exporters specializing in eco-friendly and sustainable pharmaceutical products. This trend aligns with global movements towards sustainability in healthcare.

3Demand Drivers

Norway's aging population and the increasing prevalence of chronic diseases are significant drivers of pharmaceutical import demand. The country's healthcare system's emphasis on providing comprehensive care to its citizens necessitates a steady supply of diverse pharmaceutical products.

Healthcare spending trends in Norway indicate a growing allocation towards pharmaceuticals, reflecting the sector's importance in the overall healthcare expenditure. This trend underscores the potential for increased imports of pharmaceutical products, including those from India.

TransData Nexus Research · DGFT trade data analysisMar 2026

Trade Policy & Tariff Intelligence — India and Norway

Tariff structure, trade agreements, IP and patent landscape

1Tariff & Duty Structure

Norway, as a member of the European Economic Area (EEA), applies the EEA's Common Customs Tariff to imports, including pharmaceutical products. This tariff structure is designed to facilitate trade within the EEA while protecting domestic industries.

Pharmaceutical formulations imported into Norway are subject to the standard customs duties and value-added tax (VAT) applicable to goods entering the EEA. Importers should be aware of these rates to accurately assess the landed cost of their products.

2Trade Agreements

Norway's participation in the EEA provides it with access to the EU's trade agreements, including those related to pharmaceutical products. However, Norway does not have a free trade agreement (FTA) with India, which means that Indian pharmaceutical exports to Norway are subject to standard EEA import regulations and tariffs.

Ongoing discussions about potential trade agreements between Norway and India could impact future pharmaceutical trade dynamics. Such agreements may lead to preferential treatment or reduced tariffs for Indian pharmaceutical products, enhancing their competitiveness in the Norwegian market.

3IP & Patent Landscape

Norway's adherence to international intellectual property (IP) agreements, including the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), influences the pharmaceutical market. Patent provisions in Norway provide protection for innovative pharmaceutical products, affecting the entry of generic versions.

Data exclusivity periods grant innovators exclusive rights to market their products without generic competition, impacting the timing of generic entries. Compulsory licensing provisions, though rarely invoked, can allow for generic production under specific circumstances, balancing IP rights with public health needs.

TransData Nexus Research · Trade policy databasesMar 2026

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Data Source: Indian Customs (DGFT) export shipping bill records covering all pharmaceutical shipments from India.
2.Country Matching: Shipments to Norway identified using destination country codes from customs declarations.
3.Statistical Normalization: Values are statistically normalized to remove outlier transactions and ensure accurate market share representation.
4.Coverage: 35 verified shipments from 9 Indian exporters to 11 Norway buyers.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

9 Exporters

11 buyers tracked

Expert-Reviewed

By pharmaceutical trade specialists

India to Norway Pharmaceutical Export